MARKET

ALPN

ALPN

Alpine Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.55
-1.16
-9.13%
After Hours: 11.55 0 0.00% 16:08 01/26 EST
OPEN
12.75
PREV CLOSE
12.71
HIGH
12.99
LOW
11.39
VOLUME
171.02K
TURNOVER
--
52 WEEK HIGH
16.37
52 WEEK LOW
2.050
MARKET CAP
274.93M
P/E (TTM)
-8.0348
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Alpine Immune Sciences Announces Executive Leadership Addition and Promotion
Alpine Immune Sciences Announces Executive Leadership Addition and Promotion
Business Wire · 01/06 13:00
Alpine Immune Sciences Announces Executive Leadership Addition and Promotion
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the appointment of Pamela Holland, Ph.D., as Senior Vic...
BusinessWire · 01/06 10:00
Tenax Therapeutics, Regional Health Properties leads healthcare gainers; Arcturus Therapeutics, Actinium Pharmaceuticals among major losers
Gainers: Tenax Therapeutics (TENX) +132%, Regional Health Properties (RHE) +38%, IRIDEX (IRIX) +22%, INmune Bio (INMB) +17%, Mirum Pharmaceuticals (MIRM) +8%.Losers: Arcturus Therapeutics (ARCT) -53%, Actinium Pharmaceuticals (ATNM) -24%, Alpine Immune Sciences (ALPN) -17%, Inhibikase Therapeutics (IKT) -16%, Seelos Therapeutics (SEEL)
Seekingalpha · 12/29/2020 16:03
Avidity Partners Management Reports In 13G Filing A 5.6% Stake In Alpine Immune Sciences
-SEC Filing
SEC Filing · 12/23/2020 21:11
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)
Benzinga · 12/22/2020 12:45
Benzinga's Top Upgrades, Downgrades For December 21, 2020
Benzinga · 12/21/2020 15:07
Need To Know: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Insiders Have Been Buying Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Simply Wall St. · 12/21/2020 04:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALPN. Analyze the recent business situations of Alpine Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALPN stock price target is 21.40 with a high estimate of 27.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 13.98M
% Owned: 58.74%
Shares Outstanding: 23.80M
TypeInstitutionsShares
Increased
10
334.50K
New
21
5.17M
Decreased
3
49.91K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Chief Executive Officer/Chief Compliance Officer/Executive Director
Mitchell Gold
President
Stanford Peng
Chief Financial Officer/Senior Vice President/Secretary
Paul Rickey
Senior Vice President
Pamela Holland
Chief Technology Officer
Wayne Gombotz
Other
Remy Durand
Independent Director
Min Cui
Director
Natasha Hernday
Director
Jay Venkatesan
Independent Director
Robert Conway
Independent Director
Xiangmin Cui
Independent Director
Christopher Peetz
Independent Director
Peter Thompson
Independent Director
James Topper
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ALPN
Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.

Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.